Efficacy of flibanserin 100mg qhs as a potential treatment for Hypoactive Sexual Desire Disorder
in North American pre-menopausal women.
Addyi is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder
(HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to:
2] Clayton AH, Goldfischer ER, Goldstein I, DeRogatis L, Lewis-D'Agostino D, Pyke R: Validation of the Decreased Sexual Desire Screener (DSDS): a brief diagnostic instrument for generalized acquired female Hypoactive Sexual Desire Disorder
The company's lead compound, Lorexys, recently completed a Phase IIa clinical trial for the treatment of hypoactive sexual desire disorder
Even the Score is an advocacy campaign created to serve as a voice for American women and couples who believe that it's time for the FDA to level the playing field when it comes to the treatment of hypoactive sexual desire disorder
Last fall, they heard firsthand from women living with Hypoactive Sexual Desire Disorder
about the negative impact of the condition on relationships and, by extension, on entire families.
About Hypoactive Sexual Desire Disorder
(HSDD) HSDD is the most commonly reported form of female sexual dysfunction.
5, 2015 /PRNewswire-iReach/ -- The report " Female Hypoactive Sexual Desire Disorder
C Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Female Hypoactive Sexual Desire Disorder
NASDAQ: BPAX) commented today that the recommendation on June 18, 2010 by the FDA Advisory Committee regarding the safety and efficacy of flibanserin (Boehringer-Ingelheim) will have no impact on its own ongoing development program or approval pathway for LibiGel (testosterone gel), for the treatment of hypoactive sexual desire disorder
Sprout is pursuing the FDA approval of flibanserin, which would be the first drug approved to treat Hypoactive Sexual Desire Disorder
(HSDD), the most common female sexual dysfunction, in premenopausal women.
BioSante is in Phase III development of LibiGel for the treatment of hypoactive sexual desire disorder
(HSDD) in menopausal women under an FDA approved SPA (Special Protocol Assessment).
Her passion and commitment to address this longstanding unmet medical need is unmatched as witnessed by the emerging dialogue that respects the scientific evidence and the experiences of women living with Hypoactive Sexual Desire Disorder